Global Prurigo Nodularis Treatment Market, By Treatment (Medication, Cryotherapy, Phototherapy, Pulsed Dye Laser, Others), Diagnosis (Skin Biopsy, Blood Tests, Others), Dosage (Injection, Tablets, Ointments, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Industry Trends and Forecast to 2029.
Market Analysis and Size
The number of cases of prurigo nodularis has risen dramatically in recent years owing to the rising cases of skin infections. Prurigo nodularis is a skin disorder marked by itchy, hard lumps on the surface of the skin. It affects persons of all ages, but primarily adults between the ages of 20 and 60. Iron deficiency anaemia, gluten enteropathy, chronic renal failure, HIV infection, and other disorders have all been linked to it. All these factors result in the high risk of prurigo nodularis. Therefore, this will led to the introduction of prurigo nodularis treatment in the market.
- Prurigo nodularis is a skin disorder that generates pimples on the body that are red, itchy, and occasionally painful. Although the exact aetiology of this disease is unknown, many studies believe it is caused by an allergic reaction to anything from laundry detergent to dogs to high pollen counts to nickel found in coins, jewellery, and clothing. Topical or intralesional steroids are commonly used in treatment. Phototherapy or systemic immunosuppressives are frequently used in more severe or treatment-resistant instances. In severe cases, both thalidomide and lenalidomide can be taken, but their toxicity makes them less desirable. Opioid receptor antagonists and neurokinin-1 receptor antagonists are two possible treatment medicines for prurigo nodularis that have a lower toxicity profile than thalidomide or lenalidomide.
- Data Bridge Market Research analyses that the chorioretinitis treatment market was valued at USD 1.14 billion in 2021 and is expected to reach USD 1.54 billion by 2029, registering a CAGR of 3.86% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, import/export analysis, pipeline analysis, production consumption analysis, and climate chain scenario.
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Treatment (Medication, Cryotherapy, Phototherapy, Pulsed dye laser, Others), Diagnosis (Skin Biopsy, Blood Tests, Others), Dosage (Injection, Tablets, Ointments, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
Novartis AG (Switzerland), AstraZeneca (UK), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Allergan (Ireland), LEO Pharma A/S (Denmark), Cipla Inc. (US), Eli Lilly and Company (US), Bayer AG (Germany), Abbott (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson Private Limited (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US)
Prurigo Nodularis Treatment Market Dynamics
High prevalence rate of chronic diseases
The rise in prevalence rate of chronic diseases such as diabetes, chronic kidney failure, lymphoma, lichen planus, HIV, neurological disorders and others will act as a major driver that will result in the expansion of the growth rate of the market.
Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of prurigo nodularis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness and rising number of geriatric population are the factors that will expand the prurigo nodularis treatment market. Other factors such as continuous changing lifestyle and high disposable income will positively impact the prurigo nodularis treatment market's growth rate. Additionally, increasing focus on orphan drug development and rising prevalence of prurigo nodularis treatment market in developing nations will result in the expansion of market’s growth rate.
The rise of the prurigo nodularis treatment market will be aided by advances in research and development activities for new product innovation.
The advancements in prurigo nodularis treatment research will boost new opportunities for the market's growth rate. Pharmaceutical manufacturers are always focusing on drug and therapy research and development in order to provide optimal treatment outcomes.
Moreover, surging number of strategic collaborations public and private organizations for R&D activities and development of cost-effective drugs will provide beneficial opportunities for the prurigo nodularis treatment market in the forecast period of 2022-2029.
However, high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of prurigo nodularis treatment market. Additionally, the dearth of expertise related to treatment process will hinder the prurigo nodularis treatment market growth. The lack of approved targeted therapy or diagnosis and less awareness in patients will further challenge the market in the forecast period mentioned above.
This prurigo nodularis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on prurigo nodularis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The exact number of people who suffer with PN is unknown. Although many cases in other age groups have been documented, the bulk of patients with PN present between the ages of 51 and 65. While the condition affects both men and women, it appears to be more common and severe in women. Individuals with an atopic propensity have a younger onset age, according to multiple research. Individuals of African-American ethnicity are 3.4 times more likely than white patients to suffer prurigo nodularis, suggesting that ethnicity and genetic predisposition play a role. Internal malignancy, renal failure, and psychological disorders have all been linked to the development of prurigo nodularis.
Prurigo nodularis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Prurigo Nodularis Treatment Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of prurigo nodularis treatment in recent months.
In May 2020, Sanofi had received the U.S. Food and Drug Administration (FDA) approval for first biologics medicine named Dupixent (dupilumab). It is a treatment for moderate-to-severe atopic dermatitis in children aged 6 to 11 years old whose illness is not well managed by topical prescription medications or when those therapies are not recommended. For this patient population, Dupixent is the only biologic medication approved. Dupixent is an immunosuppressive monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. IL-4 and IL-13 are essential drivers of type 2 inflammation, which plays a substantial role in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, according to data from Dupixent clinical trials. Dupixent has been used to treat over 150,000 patients worldwide across all approved indications.
Global Prurigo Nodularis Treatment Market Scope
The prurigo nodularis treatment market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Pulsed Dye Laser
On the basis of treatment, the prurigo nodularis treatment market is segmented into medication, cryotherapy, phototherapy, pulsed dye laser, and others. The medication segment is further segmented into antibiotics, emollients, oral antihistamines, corticosteroids and others.
- Skin Biopsy
- Blood Tests
On the basis of diagnosis, the prurigo nodularis treatment market is segmented into skin biopsy, blood tests and others.
On the basis of dosage, the prurigo nodularis treatment market is segmented into injection, tablets, ointments and others.
Route of Administration
On the basis of route of administration, the prurigo nodularis treatment market is segmented into oral, parenteral, topical and others.
On the basis of end-users, the prurigo nodularis treatment market is segmented into clinic, hospital and others.
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The prurigo nodularis treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Prurigo Nodularis Treatment Market Regional Analysis/Insights
The prurigo nodularis treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the prurigo nodularis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the prurigo nodularis treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.
Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increasing patient pool, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Prurigo Nodularis Treatment Market Share Analysis
The prurigo nodularis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prurigo nodularis treatment market.
Some of the major players operating in the prurigo nodularis treatment market are Novartis AG (Switzerland), AstraZeneca (UK), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Allergan (Ireland), LEO Pharma A/S (Denmark), Cipla Inc. (US), Eli Lilly and Company (US), Bayer AG (Germany), Abbott (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson Private Limited (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), and Mylan N.V. (US), among others.
Research Methodology : Global Prurigo Nodularis Treatment Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available : Global Prurigo Nodularis Treatment Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.